Clinical trial NCT01769313: A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery
Official title: A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cataract
Keywords: Cataract
Laser-assisted
Femtosecond
Lead sponsor: Technolas Perfect Vision GmbH
Sponsor class: INDUSTRY
First posted: 2013-01-16
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This clinical study (non AMG/non MPG) is a contralateral, comparative, randomized, prospective, single-center, multi-surgeon, investigator masked study to investigate whether the femtolaser cataract surgery causes any significant differences in the resulting Intra Ocular Lens overlap (ΔROverlap) as compared to the conventional, manual continuous curvilinear capsulorhexis (CCC). The Intra Ocular Lens overlap (ΔROverlap) is defined as the difference between the Intra Ocular Lens center of mass to the capsulotomy aperture center of mass.

Detailed description: A detailed pre-operative examination will ensure that every interested and willing patient fulfills the inclusion criteria of this study. For the proposed contralateral eye study between 30 and 35 patients will be enrolled whereas one eye will randomized undergo a manual cataract surgery and the other one a laser assisted cataract surgery. In total between 60 and 70 eyes will be included in the study. Pre-operative examinations are included to confirm to the clinical practice. Examinations on the day of surgery and any occurrence during the procedure are also listed. Post-operative examinations, which should document any occurrence, the outcome of and possible differences between the treatment techniques, are to be carried out after 1 day, 1 week, 1 month, 3 months and 6 months. After 6 month a final report including the study results will be produced.

The study is carried out in compliance with MEDDEV 2.7.1 Evaluation of Clinical Data: A Guide for Manufacturers and Notified Bodies, ICH E6 (R1) Good Clinical Practice (GCP), Declaration of Helsinki as well as the applicable local regulations such as notification requirements and current order of profession of the primary investigators.

Eligibility criteria: Inclusion Criteria:

* Clear corneal media
* Patients must be at least 18 years of age
* Patients must have read, understood and signed the Patient Information
* Patients are willing and able to return for follow-up examinations
* Topographic Astigmatism ≤ 1.5 dpt
* Patient will get a monofocal IOL (Envista) implanted

Exclusion Criteria:

* On a keratometric map of the cornea, the minimal and maximal K-values of the central 3mm zone must not differ by more than 5D (exclusion criterium for Group A only)
* The maximum K- value may not exceed 60D, the minimal value may not be smaller than 37D (exclusion criterium for Group A only)
* Corneal disease or pathology, such as corneal scaring or opacity, that precludes transmission of laser wavelength or that distorts laser light (exclusion criteria for Group A only)
* Subjects with a poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally
* Lens/zonular instability such as, but not restricted to, Marfan's Syndrome, Pseudoexfoliation Syndrome, etc.
* Manifest Glaucoma
* Patients presenting a clear lens (clear lens exchange)
* Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye
* Known sensitivity to planned concomitant medications
* Patients with disorders of the ocular muscle, such as nystagmus or strabismus
* Patients with keratoconus or keratectasia
* Patients with connective tissue weakness
* Patients who are blind on one eye
* Subjects who are immune compromised or carrying diagnosis of connective tissue disease, clinically significant atopic disease, insulin dependent diabetes mellitus, autoimmune diseases, ocular herpes zoster or simplex, endocrine diseases, lupus, rheumatoid arthritis, collagenosis and other acute or chronic illnesses that will increase the risk to the subject or confound the outcomes of this study.
* Abnormal examination results from slit lamp, fundus examination or IOL Master, age related changes are acceptable
* Abnormal examination results from Orbscan (exclusion criteria for Group A only; , age related changes are acceptable
* Patients who are pregnant or nursing
* Patients who do not give informed consent
* Patients with concentration disorders, epilepsy and other complicating diseases
* Patients regularly taking medicines that could influence the result of the treatment
* Patients who are participating in another ophthalmological clinical study
* Patients with an anterior chamber depth (ACD) \< 1.5 mm or ACD \> 4.8 mm as measured as from the corneal endothelium.

Primary outcomes:
measure: ΔROverlap is different between Group A and Group B
timeFrame: 6 Month postoeprative
Secondary outcomes:
measure: ΔELP is different between Group A and Group B
timeFrame: 6 months postoperative
measure: ΔFlare is different between Group A and Group B
timeFrame: 6 months postoperative
measure: SEQ Prediction Error is different between Group A and Group B
timeFrame: 6 months postoperatvie
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Universitäts-Augenklinik Heidelberg
Study officials:
affiliation: Universitäts-Augenklinik Heidelberg
name: Gerd U Auffarth, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References: